Shufang Liu

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy

Eunice S. Wang, Pau Montesinos, Mark D. Minden et al. · Blood · 2022 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate

Josef S Smolen, Désirée van der Heijde, Edward Keystone et al. · Annals of the Rheumatic Diseases · 2012 · 62 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension

Edward Keystone, Ferdinand C. Breedveld, Désirée van der Heijde et al. · The Journal of Rheumatology · 2013 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Jordi Esteve, Rik Schots, Je‐Hwan Lee et al. · Blood · 2018 · 51 citations

Medicine, Pharmacology, Pharmacotherapy +16

Translational plasma stomatology: applications of cold atmospheric plasmas in dentistry and their extension

He‐Ping Li, Xiao‐Fei Zhang, Xiaoming Zhu et al. · High Voltage · 2017 · 50 citations · Full text

Dentistry, Oral Health Sciences, Oral Medicine +11